Key facts
- This page summarizes Jason Lettmann's Form 4 filing for ALX ONCOLOGY HOLDINGS INC (ALXO).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 18 Aug 2026, 17:51.
Jason Lettmann - 17 Aug 2026 Form 4 Insider Report for ALX ONCOLOGY HOLDINGS INC (ALXO)
- Reporting relationship
- CHIEF EXECUTIVE OFFICER, Director
- Issuer ticker
- ALXO
- Reported as of
- 17 Aug 2026
- Net transaction value
- -$4,304
- SEC form
- 4
- Accepted by SEC
- 18 Aug 2026, 17:51:24 UTC
- Prior SEC filing
- 23 Mar 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Shelly Wong, by power of attorney
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Jason Lettmann filed Form 4 for ALX ONCOLOGY HOLDINGS INC (ALXO) on 18 Aug 2026.
Change
- Previous filing in this sequence was filed on 23 Mar 2026.
- Current net transaction value: -$4,304.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001688269
Primary reporting owner
Lettmann Jason
- Relationship
- CHIEF EXECUTIVE OFFICER, Director
- Address
- C/O ALX ONCOLOGY HOLDINGS INC., 323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
- Signature
- /s/ Shelly Wong, by power of attorney
- Signature date
- 18 Aug 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ALXO
transaction
Common Stock
Sale
- Transaction value
- $4,304
- Shares
- -2,230
- Change %
- -0.75%
- Price
- $1.93
- Shares after
- 294,379
- Date
- 17 Aug 2026
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units.
Footnote F2
Includes 3,000 shares acquired under the Issuer's employee stock purchase plan on June 30, 2026.